Market Cap 121.15B
Revenue (ttm) 12.00B
Net Income (ttm) 3.95B
EPS (ttm) N/A
PE Ratio 28.58
Forward PE 27.64
Profit Margin 32.94%
Debt to Equity Ratio 0.00
Volume 1,006,600
Avg Vol 1,458,924
Day's Range N/A - N/A
Shares Out 254.03M
Stochastic %K 45%
Beta 0.30
Analysts Strong Sell
Price Target $533.12

Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 341 6100
Address:
50 Northern Avenue, Boston, United States
Prester_John
Prester_John Feb. 22 at 4:36 PM
$VRTX Chris Fox, the Washington lobbyist who serves as executive director of Voices for Non-Opioid Choices. Fox has traveled to state capitals around the country to lobby for the bills. Recently, he had a personal experience with pain medications following oral surgery. “For everything but the non-opioid, my out-of-pocket expectation was $0,” he said. He was charged $30 out-of-pocket for the non-opioid. His oral surgeon wasn’t familiar with the availability of the new first-in-class non-opioid suzetrigine, Fox added. When he asked the doctor for a prescription for it, the surgeon wrote it but also prescribed an opioid along with an antibiotic. “He prescribed me hydrocodone to go along with it, just in case, because he wasn’t as familiar with [suzetrigine],” Fox said. Preventing Addiction As he spoke with Stateline by phone, Fox was driving to the local sheriff’s office to drop off the hydrocodone, which he didn’t take following his surgery. https://www.governing.com/policy/states-push-insurers-to-cover-non-opioid-pain-treatments
0 · Reply
svertical1
svertical1 Feb. 19 at 7:12 PM
$VRTX Any day?
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 19 at 3:32 AM
$VRTX Current Stock Price: $470.26 Contracts to trade: $470.0 VRTX Feb 20 2026 Call Entry: $6.40 Exit: $8.04 ROI: 26% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
pflory23
pflory23 Feb. 18 at 4:04 PM
$VRTX I’m seeing ads on Amazon video. Long for a while and a nice juicy dip here off of a strong ER.
1 · Reply
svertical1
svertical1 Feb. 18 at 3:08 PM
$VRTX Should be getting news on 60 day FDA Voucher! 60 Days in FDA Bureaucratic speak could be….?? Over/Under 6 Months?
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 18 at 2:49 PM
$VRTX RSI: 45.58, MACD: 3.9008 Vol: 7.67, MA20: 470.63, MA50: 460.80 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
RunnerSignals
RunnerSignals Feb. 17 at 8:27 PM
Selective Upgrade Strength $ABNB $VRTX $UPWK $TMC $SYF 15–80% upside implied. volume mostly in line. relative strength improving vs sector peers. pullbacks likely buyable if flows persist https://stocksrunner.com/news/2026-02-17-top-stock-upgrades-today-in-the-buzz-spotlight
0 · Reply
Otha_X
Otha_X Feb. 17 at 1:31 PM
$VRTX EPS 15.32, I’m long, dip buyers defend 460.32 😈
1 · Reply
Prester_John
Prester_John Feb. 16 at 5:03 PM
$VRTX Interesting from earnings call "With regard to WuXi and indication, we specifically did not share, so I am going to keep that information under wraps for a little bit longer. I will say that the idea of having a medicine like Povi, a pipeline-in-a-product for multiple B cell–mediated diseases, is exciting. And our interest in serial innovation stands. And you put those two together, it is probably unsurprising to you that we are interested in these kind of tri-specific engagers, because they would work for a variety of diseases, not just the ones that we talked about—IgAN, membranous, myasthenia—but other B cell–mediated diseases that we are interested in. But I will keep the specifics under wraps for a little longer. " There is a long list of these!
0 · Reply
Gostrongx
Gostrongx Feb. 16 at 2:04 PM
$CRSP when is this company be finally bought? It’s been years t alking about this tech and stock price don’t reflect. $VRTX need to not just be a partner but the owner. Wondering if that is why another suitor doesn’t appear
2 · Reply
Latest News on VRTX
Vertex Q4 Earnings Preview: What To Expect This Week

Feb 9, 2026, 11:30 AM EST - 14 days ago

Vertex Q4 Earnings Preview: What To Expect This Week


Best Defensive Stocks To Balance Tech Sector Volatility

Dec 18, 2025, 8:30 AM EST - 2 months ago

Best Defensive Stocks To Balance Tech Sector Volatility

BIP INCY MU RSP XLK


Columbia Contrarian Core Fund Q3 2025 Performance Review

Nov 18, 2025, 6:40 AM EST - 3 months ago

Columbia Contrarian Core Fund Q3 2025 Performance Review

EA EBAY ELV INTU TEL


Committee stocks on the move: Uber and Vertex Pharma

Nov 4, 2025, 1:22 PM EST - 3 months ago

Committee stocks on the move: Uber and Vertex Pharma

UBER


Columbia Balanced Fund Q3 2025 Portfolio Update

Nov 4, 2025, 2:30 AM EST - 3 months ago

Columbia Balanced Fund Q3 2025 Portfolio Update

EA EBAY ELV INTU TEL


Vertex Reports Third Quarter 2025 Financial Results

Nov 3, 2025, 4:02 PM EST - 3 months ago

Vertex Reports Third Quarter 2025 Financial Results


Vertex Pharmaceuticals Remains A Buy Heading Into Q3 Earnings

Oct 28, 2025, 11:59 AM EDT - 4 months ago

Vertex Pharmaceuticals Remains A Buy Heading Into Q3 Earnings


Final Trades: ServiceNow, Vertex Pharmaceuticals and the IJR

Oct 2, 2025, 1:31 PM EDT - 5 months ago

Final Trades: ServiceNow, Vertex Pharmaceuticals and the IJR

IJR NOW


Vertex Announces Key Advancements Across Kidney Portfolio

Sep 25, 2025, 7:45 AM EDT - 5 months ago

Vertex Announces Key Advancements Across Kidney Portfolio


Calls of the Day: Abbvie, Vertex, Veeva and Vistra

Sep 8, 2025, 1:47 PM EDT - 5 months ago

Calls of the Day: Abbvie, Vertex, Veeva and Vistra

ABBV VEEV VST


Prester_John
Prester_John Feb. 22 at 4:36 PM
$VRTX Chris Fox, the Washington lobbyist who serves as executive director of Voices for Non-Opioid Choices. Fox has traveled to state capitals around the country to lobby for the bills. Recently, he had a personal experience with pain medications following oral surgery. “For everything but the non-opioid, my out-of-pocket expectation was $0,” he said. He was charged $30 out-of-pocket for the non-opioid. His oral surgeon wasn’t familiar with the availability of the new first-in-class non-opioid suzetrigine, Fox added. When he asked the doctor for a prescription for it, the surgeon wrote it but also prescribed an opioid along with an antibiotic. “He prescribed me hydrocodone to go along with it, just in case, because he wasn’t as familiar with [suzetrigine],” Fox said. Preventing Addiction As he spoke with Stateline by phone, Fox was driving to the local sheriff’s office to drop off the hydrocodone, which he didn’t take following his surgery. https://www.governing.com/policy/states-push-insurers-to-cover-non-opioid-pain-treatments
0 · Reply
svertical1
svertical1 Feb. 19 at 7:12 PM
$VRTX Any day?
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 19 at 3:32 AM
$VRTX Current Stock Price: $470.26 Contracts to trade: $470.0 VRTX Feb 20 2026 Call Entry: $6.40 Exit: $8.04 ROI: 26% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
pflory23
pflory23 Feb. 18 at 4:04 PM
$VRTX I’m seeing ads on Amazon video. Long for a while and a nice juicy dip here off of a strong ER.
1 · Reply
svertical1
svertical1 Feb. 18 at 3:08 PM
$VRTX Should be getting news on 60 day FDA Voucher! 60 Days in FDA Bureaucratic speak could be….?? Over/Under 6 Months?
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 18 at 2:49 PM
$VRTX RSI: 45.58, MACD: 3.9008 Vol: 7.67, MA20: 470.63, MA50: 460.80 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
RunnerSignals
RunnerSignals Feb. 17 at 8:27 PM
Selective Upgrade Strength $ABNB $VRTX $UPWK $TMC $SYF 15–80% upside implied. volume mostly in line. relative strength improving vs sector peers. pullbacks likely buyable if flows persist https://stocksrunner.com/news/2026-02-17-top-stock-upgrades-today-in-the-buzz-spotlight
0 · Reply
Otha_X
Otha_X Feb. 17 at 1:31 PM
$VRTX EPS 15.32, I’m long, dip buyers defend 460.32 😈
1 · Reply
Prester_John
Prester_John Feb. 16 at 5:03 PM
$VRTX Interesting from earnings call "With regard to WuXi and indication, we specifically did not share, so I am going to keep that information under wraps for a little bit longer. I will say that the idea of having a medicine like Povi, a pipeline-in-a-product for multiple B cell–mediated diseases, is exciting. And our interest in serial innovation stands. And you put those two together, it is probably unsurprising to you that we are interested in these kind of tri-specific engagers, because they would work for a variety of diseases, not just the ones that we talked about—IgAN, membranous, myasthenia—but other B cell–mediated diseases that we are interested in. But I will keep the specifics under wraps for a little longer. " There is a long list of these!
0 · Reply
Gostrongx
Gostrongx Feb. 16 at 2:04 PM
$CRSP when is this company be finally bought? It’s been years t alking about this tech and stock price don’t reflect. $VRTX need to not just be a partner but the owner. Wondering if that is why another suitor doesn’t appear
2 · Reply
StealthAssasin
StealthAssasin Feb. 16 at 6:32 AM
0 · Reply
JuggernautRaider
JuggernautRaider Feb. 14 at 8:33 PM
$TNXP $AXSM $VRTX $ABBV well if you ask ChatGPT for the best analog to Tonmya from Tonix, it’s Auvelity from Axsome - fitting given they’re also developing a fibromyalgia drug, but a much different space. I went back and dug up CNS comparators- Tonmya is doing just as well! The chart for all in the first 10 weeks of sales looks similar (capture rate in Symphony is quite low as discussed - and samples/ “free drug” are also not included). The market makers saw the dip in sales due to the crazy winter storm and sold. The wise were buying and holding long. The next year is key, but Tonmya is on a blockbuster path when compared to other recent CNS launches. Tonmya will be a Juggernaut for fibromyalgia patients to start, and Tonix may need to fight off some buyouts if the stock stays this low 🚀 Vertex, Otsuka, AbbVie, even BMY could all buy them out 🏦 FYI @Night_Owl_Biotech @Proposition_Joe @Hoppanin @PeteyUSA @BioCapitalist99 @Duediligence20
2 · Reply
outlawinvestor1
outlawinvestor1 Feb. 14 at 4:45 PM
good point @ByBi. $TNXP tonmya vs $VRTX journavx
1 · Reply
outlawinvestor1
outlawinvestor1 Feb. 14 at 4:38 PM
$TNXP great info - amazing launch so far. $VRTX journavx is an acute pain med vs tonmya - a chronic pain med so not apples to apples, but the best recent launch comparator we have i believe.
1 · Reply
moneybag888
moneybag888 Feb. 13 at 7:07 PM
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Feb. 13 at 7:07 PM
$VRTX this is really special-lowering guidance by $5 when they received 4 upgrades this morning
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Feb. 13 at 6:31 PM
$VRTX BINGO!
0 · Reply
ZacksResearch
ZacksResearch Feb. 13 at 6:19 PM
$VRTX earnings miss — but is the market missing the bigger picture? 🤔 Q4 earnings came in below estimates, yet revenues topped forecasts on strong CF sales and momentum from newer launches like Alyftrek, Casgevy and Journavx. That kind of product strength matters more than a single-quarter EPS slip. Find out what this means for the stock’s next move 👉 https://www.zacks.com/stock/news/2869170/vrtxs-q4-earnings-miss-mark-revenues-beat-on-higher-product-sales?cid=sm-stocktwits-2-2869170-teaser-33645&ADID=SYND_STOCKTWITS_TWEET_2_2869170_TEASER_33645
0 · Reply
l4ndsh4rk
l4ndsh4rk Feb. 13 at 6:10 PM
$VRTX Oppenheimer upgrade, $540 p/t
0 · Reply
moneybag888
moneybag888 Feb. 13 at 5:51 PM
0 · Reply
ZacksResearch
ZacksResearch Feb. 13 at 5:19 PM
$VRTX misses Q4 earnings but beats on revenue, thanks to strong CF drug sales and new product contributions! 🤔 Earnings came in at $5.03/share, missing the Zacks Consensus Estimate of $5.07, but total revenues rose 10% YoY to $3.19B, driven by higher CF drug sales and new product contributions. Full breakdown here 👉 https://www.zacks.com/stock/news/2869170/vrtxs-q4-earnings-miss-mark-revenues-beat-on-higher-product-sales?cid=sm-stocktwits-2-2869170-body-33646&ADID=SYND_STOCKTWITS_TWEET_2_2869170_BODY_33646
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Feb. 13 at 4:06 PM
$VRTX might even get this earlier-maybe today is possible-LOL!
2 · Reply